XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 5,648 | $ 7,141 | $ 10,736 | $ 13,646
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 4,083 | 5,004 | 7,630 | 9,473
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1,084 | 1,458 | 2,141 | 2,817
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 481 | 679 | 965 | 1,356
Atripla |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 349 | 475 | 663 | 927
Atripla | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 274 | 334 | 502 | 650
Atripla | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 39 | 86 | 90 | 180
Atripla | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 36 | 55 | 71 | 97
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 185 | 0 | 220 | 0
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 183 | 0 | 218 | 0
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 2 | 0 | 2 | 0
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 199 | 254 | 389 | 507
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 82 | 112 | 149 | 224
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 103 | 127 | 212 | 252
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 15 | 28 | 31
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 403 | 286 | 764 | 537
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 311 | 232 | 585 | 441
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 78 | 47 | 153 | 84
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 7 | 26 | 12
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 1,160 | 857 | 2,242 | 1,626
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 904 | 710 | 1,757 | 1,379
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 207 | 125 | 393 | 212
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 49 | 22 | 92 | 35
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 385 | 258 | 727 | 485
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 303 | 230 | 582 | 433
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 77 | 27 | 135 | 50
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 5 | 1 | 10 | 2
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 187 | 293 | 361 | 602
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 144 | 225 | 277 | 451
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 34 | 54 | 63 | 121
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 9 | 14 | 21 | 30
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 765 | 812 | 1,417 | 1,526
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 649 | 567 | 1,156 | 1,031
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 86 | 184 | 183 | 373
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 30 | 61 | 78 | 122
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 19 | 11 | 32 | 26
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 11 | 7 | 20 | 21
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 3 | 2 | 4 | 3
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 5 | 2 | 8 | 2
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 13 | 0 | 20 | 0
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 13 | 0 | 20 | 0
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 103 | 92 | 210 | 184
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 8 | 31 | 17
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 55 | 50 | 111 | 102
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 34 | 34 | 68 | 65
Epclusa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 500 | 1,171 | 1,036 | 2,063
Epclusa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 239 | 864 | 508 | 1,599
Epclusa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 168 | 248 | 366 | 386
Epclusa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 93 | 59 | 162 | 78
Harvoni |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 331 | 1,382 | 679 | 2,753
Harvoni | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 230 | 984 | 464 | 1,910
Harvoni | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 22 | 230 | 78 | 473
Harvoni | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 79 | 168 | 137 | 370
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 244 | 230 | 448 | 441
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 244 | 230 | 448 | 441
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Ranexa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 208 | 200 | 403 | 353
Ranexa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 208 | 200 | 403 | 353
Ranexa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Ranexa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 76 | 22 | 134 | 33
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 59 | 21 | 106 | 32
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 3 | 1 | 6 | 1
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 0 | 22 | 0
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 82 | 300 | 179 | 560
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 16 | 141 | 23 | 258
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 32 | 76 | 62 | 147
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 34 | 83 | 94 | 155
Vosevi |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 109 | 0 | 216 | 0
Vosevi | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 86 | 0 | 172 | 0
Vosevi | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 20 | 0 | 36 | 0
Vosevi | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 3 | 0 | 8 | 0
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 68 | 0 | 108 | 0
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 68 | 0 | 108 | 0
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Zydelig |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 39 | 35 | 72 | 70
Zydelig | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 17 | 19 | 31 | 34
Zydelig | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 22 | 16 | 40 | 35
Zydelig | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 1 | 1
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 115 | 368 | 221 | 730
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 27 | 98 | 56 | 158
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 41 | 126 | 56 | 246
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 47 | 144 | 109 | 326
Product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 5,540 | 7,046 | 10,541 | 13,423
Product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 4,069 | 4,982 | 7,596 | 9,432
Product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 1,005 | 1,399 | 2,010 | 2,665
Product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 466 | 665 | 935 | 1,326
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 108 | 95 | 195 | 223
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 14 | 22 | 34 | 41
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 79 | 59 | 131 | 152
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 15 | $ 14 | $ 30 | $ 30

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsEpclusaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsHarvoniMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |